# Mustang Bio, Inc.: overview MBIO · Nasdaq · CIK 1680048 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mbio.md) · [Financials](/companies/mbio/financials.md) · [Filings](/companies/mbio/filings.md) · [Insiders](/companies/mbio/insiders.md) Latest reported revenue: [$0](/filings/0001104659-20-034130.md) for Q4 FY2019, three months to 2019-12-31, from the 10-K filed Mar 16, 2020 (XBRL us-gaap:Revenues, accession 0001104659-20-034130). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.96)](/filings/0001104659-25-108468.md) | not reported | [(0.05)](/filings/0001104659-26-055598.md) | [(0.19)](/filings/0001104659-26-091061.md) | [(0.07)](/filings/0001104659-25-108468.md) | not reported | [(0.14)](/filings/0001104659-26-055598.md) | [(0.16)](/filings/0001104659-26-091061.md) | | Free cash flow | $k | [(1,757) d](/filings/0001104659-25-108468.md) | [(1,997) d](/filings/0001104659-26-032063.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.76)](/filings/0001558370-23-004979.md) | [(10.09)](/filings/0001558370-24-002899.md) | [(299.95)](/filings/0001558370-25-003913.md) | [(38.57)](/filings/0001104659-26-032063.md) | [(0.39)](/filings/0001104659-26-032063.md) | | Free cash flow | $m | [(57.7)](/filings/0001558370-23-004979.md) | [(67.8)](/filings/0001558370-24-002899.md) | [(49.5)](/filings/0001558370-25-003913.md) | [(11.4)](/filings/0001104659-26-032063.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mbio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Kestra Advisory Services, LLC](/funds/1830819.md) | 2026-06-30 | $138.3k | 196,991 | | Added +20,949 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $59.5k | 84,745 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $41.7k | 59,459 | | Added +6,259 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $29.7k | 42,240 | | Reduced −50,550 | | [CFO4Life Group, LLC](/funds/1706351.md) | 2026-06-30 | $23.5k | 33,510 | | Added +13,049 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $22.5k | 32,120 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $18.0k | 25,704 | | Unchanged | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $10.3k | 14,648 | | New +14,648 | | [TWO SIGMA SECURITIES, LLC](/funds/1450144.md) | 2026-06-30 | $9.6k | 13,742 | | New +13,742 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $9.6k | 13,664 | | New +13,664 | ## Recent filings [All 386 filings](/companies/mbio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 20:05 ET | [8-K](/filings/0001104659-26-116233.md) | 8.01 Other events | 0001104659-26-116233 | | 2026-08-05 | 20:01 ET | [10-Q](/filings/0001104659-26-091061.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091061 | | 2026-05-05 | 20:01 ET | [10-Q](/filings/0001104659-26-055598.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055598 | | 2026-04-17 | 20:01 ET | [8-K](/filings/0001104659-26-044890.md) | 3.01 Delisting notice | 0001104659-26-044890 | | 2026-03-19 | 20:05 ET | [10-K](/filings/0001104659-26-032063.md) | Annual report, period 2025-12-31 | 0001104659-26-032063 | | 2025-12-23 | 21:05 ET | [8-K](/filings/0001104659-25-124189.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-124189 | | 2025-12-03 | 21:05 ET | [DEF 14A](/filings/0001104659-25-118122.md) | Proxy statement, period 2025-12-22 | 0001104659-25-118122 | | 2025-11-07 | 21:06 ET | [10-Q](/filings/0001104659-25-108468.md) | Quarterly report, period 2025-09-30 | 0001104659-25-108468 | | 2025-08-08 | 20:05 ET | [10-Q](/filings/0001558370-25-010920.md) | Quarterly report, period 2025-06-30 | 0001558370-25-010920 | | 2025-07-09 | 23:53 ET | [8-K](/filings/0001104659-25-066520.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-066520 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-032063.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1680048 - Tickers: MBIO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.